Clinical Trials
8 trialsNCT04304144 2025-03-05
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 2 Completed
NCT02312206 2023-11-14
VITAL
Prothena Biosciences Ltd.
Phase 3 Terminated
NCT01318902 2020-04-01
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Phase 1 Completed
NCT02603172 2019-09-23
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GlaxoSmithKline
Phase 1 Terminated
NCT02613182 2019-05-16
OLE
Prothena Biosciences Ltd.
Phase 2 Terminated
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT03154047 2019-03-26
Study in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 2 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed